Pliant Therapeutics Inc (PLRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pliant Therapeutics Inc (PLRX) has a cash flow conversion efficiency ratio of -0.087x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.80 Million) by net assets ($146.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Pliant Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Pliant Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Pliant Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pliant Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pliant Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Pliant Therapeutics Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Amogreentech Co.Ltd
KQ:125210
|
0.069x |
|
Global Education Limited
NSE:GLOBAL
|
0.078x |
|
Song Shang Electronics Co Ltd
TWO:6156
|
-0.075x |
|
Advanced Lithium Electrochemistry Cayman Co Ltd
TWO:5227
|
-0.199x |
|
Seafco Public Company Limited
BK:SEAFCO
|
0.061x |
|
Kamat Hotels (I) Limited
NSE:KAMATHOTEL
|
0.085x |
|
ALBIS Leasing AG
XETRA:ALG
|
0.093x |
|
Mospec Semiconductor Corp
TW:2434
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Pliant Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Pliant Therapeutics Inc from 2017 to 2025. View Pliant Therapeutics Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $181.21 Million | $-128.34 Million | -0.708x | -38.49% |
| 2024-12-31 | $304.08 Million | $-155.50 Million | -0.511x | -108.13% |
| 2023-12-31 | $473.58 Million | $-116.36 Million | -0.246x | +18.64% |
| 2022-12-31 | $313.34 Million | $-94.63 Million | -0.302x | +20.31% |
| 2021-12-31 | $199.06 Million | $-75.44 Million | -0.379x | -187.84% |
| 2020-12-31 | $283.06 Million | $-37.27 Million | -0.132x | -102.08% |
| 2019-12-31 | $-435.00K | $-2.75 Million | 6.322x | -80.32% |
| 2018-12-31 | $-882.00K | $-28.33 Million | 32.118x | +738.60% |
| 2017-12-31 | $3.37 Million | $-16.92 Million | -5.029x | -- |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform c… Read more